Related Experiment Video
Updated: Sep 8, 2025
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential
Luohong Li1, Jing Zhou1, Xueting Dong1
1NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan 410078, China; Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
Abstract:
Glioblastoma (GBM) is a heterogeneous and invasive WHO grade IV brain tumor. Patients with GBM have a median overall survival (OS) of only 14 to 17 months when treated with surgical resection and chemoradiation. As one of the most promising anti-tumor immunotherapies, dendritic cell (DC) vaccines have demonstrated good efficacy, safety, and tolerability in many clinical trials. However, to date, no Phase III clinical trial has achieved positive endpoints and truly implement clinical development and transformation. Moreover, the survival benefits of DC vaccines for patients with GBM seem to have a delayed effect; therefore, we urgently require strategies to optimize DC vaccines to advance the time point of its survival benefits. Here, we discuss the latest clinical trial progress of DC vaccines in GBM and summarize the benefits and drawbacks of various vaccine design options, as well as the challenges faced in clinical translation. Moreover, we target future combination therapy strategies for DC vaccines in GBM, which provides a new perspective for comprehensively understanding the effectiveness, limitations, and new directions of the development of DC vaccines.
Insights
Dendritic cell (DC) vaccines show promise for glioblastoma (GBM) but require optimization for delayed survival benefits. This review explores clinical trials, design challenges, and combination strategies for DC vaccines in GBM treatment.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Vaccines
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis, typically 14-17 months median survival.
- Dendritic cell (DC) vaccines represent a promising immunotherapy approach for GBM, showing efficacy and safety in trials.
- Despite potential, no Phase III DC vaccine trials for GBM have met endpoints, necessitating optimization strategies.
Purpose of the Study:
- To review the current clinical trial landscape of DC vaccines for GBM.
- To analyze the advantages and disadvantages of different DC vaccine designs.
- To identify challenges in clinical translation and propose future combination therapies.
Main Methods:
- Literature review of clinical trials involving DC vaccines for GBM.
- Analysis of vaccine design parameters and their impact on efficacy.
- Exploration of combination strategies with existing GBM treatments.
Main Results:
- DC vaccines demonstrate potential but face challenges in achieving timely survival benefits for GBM patients.
- Various vaccine designs offer different benefits and drawbacks, impacting clinical translation.
- Combination therapies are crucial for enhancing DC vaccine effectiveness and overcoming limitations.
Conclusions:
- Optimizing DC vaccine design and timing is essential to advance survival benefits in GBM.
- Addressing clinical translation challenges and exploring novel combination strategies are key for future development.
- Further research into combination therapies holds promise for improving outcomes in glioblastoma immunotherapy.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy